Member Info for TrickyEFC

Think pj will be right none day 💪💪

😂😂😂😂😂😂

Morning Bones

And a woo hoo.

Get the awakn deal done.

Agm on Monday. Then hopefully by Tuesday next week they will have about 3 million cash to see us progress development into late 2026.

Did say it was going up.

Thanks to the UT.

They gonna use that in morning to make us open up red 😂👏😂

That's insane

Half agree.

Reckon it's going up though

And welcome to zero.

Ya got to laugh ain't ya

Think it's about 380k m cap

Bones we need funding to be announced.

Have money for hopefully 18 months runway.

Anything over 0.12p would be great.

Ho ho ho.

Ain't water suppose to be blue in colour.

It's got to be over 0.1p 😊

It's difficult to give a precise predicted share price for Awakn Life Sciences (AWKNF) because it's a dynamic stock with a relatively low market capitalization and subject to various factors. Analyst price targets, often indicating a fair value, can range from $0.0797 to $1.75, with a high target of $1.75. However, these are just estimates and don't guarantee future performance.

AWKN-002 is a proprietary, investigational, patent-pending sublingual or buccal esketamine formulation designed for use alongside manualised behavioural therapy in patients with moderate to severe AUD. It is currently in Phase 2b planning in the US and is expected to follow the FDA's 505(b)(2) regulatory pathway.

According to PharmaVentures' market analysis, subject to the successful completion of the planned Phase 2b trial and based on similar transactions for mid-stage assets, comparable assets typically achieve a total deal value of approximately £150 million, in upfront and commercial milestone payments, plus additional future material royalties on net sales2.

The FDA's 505(b)(2) pathway is a regulatory route for drug approval that allows sponsors to leverage existing data from previously approved drugs or published literature to support their new drug application. This pathway is particularly useful for developing new drug products that are similar to existing ones but have modifications like new formulations, indications, or strengths. It can streamline the drug development process by reducing the need for extensive clinical trials and preclinical studies, potentially leading to faster approval times.

Ketamine treatment is usually given intravenously (IV) in a healthcare setting. The length of the infusion can vary depending on the severity of the pain and the response to treatment. A typical ketamine treatment session lasts for about 40 minutes. The effects of ketamine can last for hours or even days

Awakn002 may possibly be able to replace an existing treatment method that relies on IV with an OTF

FDA seems keen to see where this is going.

Update on FDA Pre-IND Meeting for Awakn Life Sciences' Drug Candidate AWKN-002

· FDA supports AWKN-002's progression to Phase 2b clinical trial without requirement for additional clinical data

· FDA endorses use of 505(b)(2) NDA pathway, enabling a streamlined regulatory process and potential for faster market access

· AWKN-002 is being developed for the treatment of alcohol use disorder in the U.S.

Prof. Celia Morgan, the principal Investigator on the study commented “The rapid onset and offset of action of AWKN-002 and the ease of clinical use that we observed in our investigative study, compared to IV ketamine has galvanized our view that this represents a way to dramatically widen access to ketamine treatment. AWKN-002 means that we may reach more of the patients that desperately need this life-saving addiction treatment”

So made use of that ai thing 😂

AI Overview

LTS Lohmann is a company, and success rates are typically discussed in the context of their products or treatments. Specifically, in the context of Awakn Life Sciences, Phase 2 results showed a 50% reduction in heavy drinking days six months after treatment, and an 86% average abstinence rate during the same period, compared to 2% pre-trial

In relation to the audit mentioning they have plenty of margin. Well if successful they have direct access to large scale production.

Lts

From bench to market, we can deliver you innovative oral and transdermal drug delivery solutions that speed your development time.

Theoretical evaluation and benchmarking

Practical feasibility studies, including prototyping.

Pharmaceutical product development.

Customized design of production lines, or development of existing equipment.

Large scale production

No red in sight tomorrow.

Have a good back from the dead weekend.

Hopefully this will come back to life sometimes soon.